Prevalence of breast malignant pathology in women more than 14 years old General surgery department - Hospital de San José, Bogotá DC, 2009

Prevalencia de patología maligna de seno en mujeres mayores de 14 años Servicio de cirugía general, Hospital de San José, Bogotá D.C., 2009

This is a descriptive cross sectional study conducted to determine the prevalence of breast malignant pathology in women more than 14 years old who consulted for a palpable solid mass in the breast to the General Surgery Department at Hospital de San José, Bogotá DC. between March 2009 and February 2010. The prevalence rate was 18.1%. Mean age was 60.1 years. Average age at onset of menopause was 50 years, age at first birth 25.8 years and number of children 1.7. Average period of time they breast fed their children was 10.5 months. There were no personal antecedents of breast cancer, and family history of this malignancy was found in 13.3% only. Sixty-five (78.3%) of the palpable solid masses were detected by self-exam. The mean time of appearance was 14.1 months (SD: 17 months) and the majority of patients reported pain as associated clinical manifestation. The predominant BIRADS classification for ultrasound and mammography in women with malignancy was type 4. The predominant result in biopsies was, infiltrating ductal carcinoma (80%), and fibroadenoma (56%), a benign condition. Surgery was the most frequently used therapeutic intervention.

1 Murillo R, Quintero A, Piñeros M, Bravo MM, et al. Modelo para el control del cancer en Colombia. Bogotá: Ministerio de la Protección Social, Institu­ to Nacional de Cancerología; 2006.
2 Brinton LA, DeVesa SS. Etiology and pathogenesis of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osbome CK, editors. Diseases of the braest. Philadelphia : Lippincott-Raven; 1996. p. 159-68.
3 Amir E, Freedman OC, Seruga B, Evans DG. Assessing womes at high risk of breast cancer: a review of risk assessment models. JNatl CancerInst. 201O; 102(10): 680-91.
4 Piñeros M, Sánchez R, Cendales R, Perry F, Ocarnpo R, García O. Caracte­ ósticas sociodemográficas, clínicas y de la atención de mujeres con cáncer de mama en Bogotá. Rev. Col. Cancero/. 2008;12 (4):181-90.
5 Feig B, Berger D, Fuhrman G. Cáncer de mama invasivo y cáncer de mama no invasivo. En: Oncología quirúrgica. Philadelphia: Marban; 2005. p. 1-40.
6 Pruthi S. Detection and evaluation of a palpable breast mass. Mayo Clin Proc. 2001;76 (6):641-647.
7 Zapardiel I, Gutierrez J, Scheneider F. ¿Sabemos que causa el cáncer de mama? Influencia actual de los diferentes factores de riesgo. Prog Obstet Ginecol. 2009;52:595-608.
8 Carrero N, Betancourth L, Bérgamo L, Pinto Y, Díaz F, Gonzalez C, et al. Perfil clínico patológico del servicio de patología mamaria. Rev Venez Oncol. 2008;3:86-91.
9 Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, et al. Genetic / familia] high-risk assessment: breast and ovarían. J Natl Compr Canc Netw 2010;8:562-594.
10 MeisnerAL, Fekrazad MH, Royce ME. Breast disease: benignand malignant. Med Clin NorthAm. 2008;92:1115-41.
11 Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez A. Influence on delay on survival in patients with breast cancer: a systematic review. Lancet. 1999; 353 (3): 1119-26.
12 Hansen NM, GrowneyA. Breastcancer: pre- and postoperative imaging for staging. Surg Oncol Clin NAm. 2007;16:447-63.
13 Yeh ED. Breast magnetic resonance imaging: curren! clínica] indications. Magn Reson lmaging Clin N Am. 2010; 18(2): 155-69.
14 Klein S. Evaluation of palpable breast masses. Am Fam Physician.
2005;71:1731-38.
15 Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology. 1999;211:845-50.
16 Angarita FA, Acuña SA, Tawil M, Ruiz AJ, Torreglosa L. presentación inicial de las pacientes con cancer de seno en el Centro Javeriano de Oncología, Hospital Universitario San Ignacio. Rev Colomb Cir. 2010; 25(1): 19-26.
17 Angarita F, Acuña S. Cáncer de Seno: de la epidemiología al tratamiento. Univ Med. 2008;49:344-72.